[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"WEI XU\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":72},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,49],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100651765","r-ma-pd-1-versus-r-ma-in-treatment-naive-primary-cns-lymphoma-100651765",false,"NCT07764601","R-MA-PD-1 Versus R-MA in Treatment-naive Primary CNS Lymphoma","A Prospective, Open-label, Randomized Controlled Study Comparing Rituximab, Methotrexate, Cytarabine, and Penpulimab (R-MA-PD-1) Versus Rituximab, Methotrexate, and Cytarabine (R-MA) in Treatment-naive Patients With Primary Central Nervous System Lymphoma","RM-MA-PD1","Inclusion Criteria:\n\n1. Fully understands the study and voluntarily signs informed consent.\n2. Age 18 to 80 years.\n3. Treatment-naive, pathologically (immunophenotypically) confirmed PCNSL (per 2016 WHO classification).\n4. Diffuse large B-cell lymphoma originating in the CNS without other organ involvement, confirmed by PET-CT or contrast-enhanced CT.\n5. Expected survival more than 3 months.\n6. Laboratory: creatinine clearance ≥50 mL\u002Fmin (Cockcroft-Gault); INR ≤1.5 x ULN or aPTT ≤1.5 x ULN (INR 2-3 allowed if on warfarin); LVEF ≥50%.\n7. GFR ≥60 mL\u002Fmin.\n8. Participants of childbearing potential must agree to use effective contraception during the study and for 30 days after the last dose.\n\nExclusion Criteria:\n\n1. Contraindication to any study drug.\n2. Clinically significant liver disease, including viral or other hepatitis or cirrhosis (active HBV or active hepatitis C as defined).\n3. HIV infection.\n4. History of allergic disease, severe drug allergy, or known hypersensitivity to macromolecular protein preparations or any component of penpulimab.\n5. Prior anti-PD-1\u002FPD-L1\u002FPD-L2, anti-CTLA-4 antibody, CAR-T, or any other agent targeting T-cell co-stimulation or checkpoint pathways.\n6. Congestive heart failure (NYHA \\>2); acute myocardial infarction, unstable angina, stroke, or transient ischemic attack within 6 months.\n7. Congenital long QT syndrome or QTcF \\>480 ms.\n8. Other malignancy within the past 5 years (except adequately treated in situ cervical carcinoma, basal cell skin carcinoma, in situ breast carcinoma, or a second primary cancer cured and recurrence-free for 5 years).\n9. Pregnant or lactating women, or intending to become pregnant during the study.\n10. History of clinically significant neurological or psychiatric disorder, or substance\u002Fdrug abuse.\n11. Clinically significant active infection.","ALL","18 Years","80 Years",{"count":21,"type":22},58,"ESTIMATED","INTERVENTIONAL",[25],"NA","This is a prospective, open-label, multicenter, randomized controlled study in treatment-naive patients with primary central nervous system lymphoma (PCNSL, DLBCL type). Eligible participants are randomized 1:1 to the experimental arm (R-MA-PD-1: rituximab, methotrexate, cytarabine plus penpulimab) or the control arm (R-MA: rituximab, methotrexate, cytarabine). Induction is administered every 21 days for 6 cycles, followed by risk- and response-adapted consolidation (ASCT or whole-brain radiotherapy) and penpulimab maintenance. The primary objective is to compare the 2-year progression-free survival rate between the two arms.",[28,29],"Primary Central Nervous System Lymphoma","Diffuse Large B-Cell Lymphoma",[31,32,33,34,35],"PCNSL","Penpulimab","PD-1 inhibitor","High-dose methotrexate","Rituximab","NOT_YET_RECRUITING","2026-08-12",{"date":39,"type":40},"2026-08-14","ACTUAL",{"date":42,"type":22},"2026-08",{"date":44,"type":22},"2029-08",{"name":46,"class":47},"WEI XU","OTHER",5,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":56,"enrollmentInfo":57,"targetDuration":4,"studyType":23,"phases":59,"briefSummary":61,"conditions":62,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":4},"100622620","phase-2-golidocitinib-combined-with-p-gemox-plus-pd-1-inhibitor-versus-p-gemox-plus-pd-1-inhibitor-in-first-line-newly-diagnosed-advanced-or-non-nasal-extranodal-nkt-cell-lymphoma-100622620","NCT07385989","Golidocitinib Combined With P-GemOx Plus PD-1 Inhibitor Versus P-GemOx Plus PD-1 Inhibitor in First-Line Newly Diagnosed Advanced or Non-Nasal Extranodal NK\u002FT-Cell Lymphoma","A Randomized Controlled Multicenter Phase 2 Clinical Trial of Golidocitinib Combined With P-GemOx Plus PD-1 Inhibitor Versus P-GemOx Plus PD-1 Inhibitor in the Treatment of First-Line Newly Diagnosed Advanced Extranodal NK\u002FT-Cell Lymphoma (ENKTL) or Non-Nasal Extranodal NK\u002FT-Cell Lymphoma (ENKTL)","Inclusion Criteria:\n\n1. Voluntarily provides written informed consent (ICF) prior to any study procedures.\n2. Aged 18-70 years (inclusive), regardless of sex.\n3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n4. Histologically confirmed extranodal NK\u002FT-cell lymphoma (ENKTL), staged as Stage III-IV or non-nasal ENKTL (per 2016 WHO Classification of Hematopoietic and Lymphoid Tumors).\n5. At least one measurable\u002Fevaluable lesion (per 2014 Lugano Classification: measurable lesion ≥1.5 cm in longest diameter + ≥1.0 cm in shortest diameter; evaluable lesion with FDG uptake higher than liver on PET\u002FCT).\n6. Treatment-naive (no prior anti-cancer therapy for ENKTL).\n7. Adequate organ function:\n\n   AST\u002FALT ≤2.5×upper limit of normal (ULN); Total bilirubin (TBIL) ≤1.5×ULN; Serum creatinine \\\u003C1.5×ULN or creatinine clearance (CrCl, via Cockcroft-Gault formula) ≥60 mL\u002Fmin.\n8. Reproductive-aged females have a negative pregnancy test at screening; all participants use effective contraception during the study and for 12 months after the last dose.\n9. Expected survival ≥6 months.\n\nExclusion Criteria:\n\n1. Complicated by hemophagocytic lymphohistiocytosis (HLH) or aggressive NK-cell leukemia.\n2. Contraindication to golidocitinib, PD-1 inhibitor, or any component of the P-GEMOX regimen.\n3. Lymphoma involvement of the central nervous system (CNS).\n4. Major surgery (excluding diagnostic biopsy) within 4 weeks prior to study treatment initiation.\n5. History of other malignant tumors (except curatively treated in situ cancers, e.g., cervical carcinoma in situ) within 5 years.\n6. Uncontrolled severe comorbidities (e.g., NYHA Class II+ heart failure, unstable angina, myocardial infarction within 1 year, uncontrolled arrhythmias).\n7. Active bleeding (e.g., gastrointestinal hemorrhage, cerebral hemorrhage).\n8. Uncontrolled infection (requiring parenteral anti-infective therapy) within 7 days prior to study treatment.\n9. Active hepatitis B\u002FC: HBsAg+\u002FHBcAb+ with HBV-DNA \\>2500 copies\u002FmL (or 500 IU\u002FmL); HCV antibody+ with positive HCV-RNA.\n10. HIV infection or acquired immunodeficiency syndrome (AIDS).\n11. Conditions impairing drug absorption (e.g., inability to swallow tablets, malabsorption syndrome).\n12. Pregnant\u002Flactating females, or reproductive-aged participants refusing contraception.\n13. Psychiatric illness precluding informed consent or study compliance.\n14. Other conditions deemed unsuitable for enrollment by the investigator.","70 Years",{"count":58,"type":22},40,[60],"PHASE2","This is a multicenter, randomized, Phase 2 clinical trial designed to evaluate the efficacy and safety of golidocitinib combined with the P-GemOx (pegaspargase + gemcitabine + oxaliplatin) regimen plus PD-1 inhibitor, compared with P-GemOx plus PD-1 inhibitor alone, in participants with first-line newly diagnosed advanced (Stage III-IV) or non-nasal extranodal natural killer\u002FT-cell lymphoma (ENKTL). Eligible participants will be randomly assigned 1:1 to two groups:\n\nExperimental group: Golidocitinib (150 mg orally once daily, Days 1-21 per 21-day cycle) + P-GemOx (pegaspargase 2000 U\u002Fm² on Day 2; gemcitabine 1000 mg\u002Fm² on Day 1; oxaliplatin 100 mg\u002Fm² on Day 1, per 21-day cycle) + PD-1 inhibitor (200 mg intravenously on Day 1 per 21-day cycle).\n\nControl group: P-GemOx + PD-1 inhibitor (same dosage\u002Fschedule as the experimental group, without golidocitinib). All participants will receive 6 cycles of induction therapy. Those achieving CR or partial response (PR) after induction will receive maintenance therapy for 1 year: the experimental group will continue golidocitinib + PD-1 inhibitor, while the control group will receive PD-1 inhibitor alone (both per 21-day cycles). The primary outcome is the complete response rate (CRR) after 6 induction cycles (assessed per the 2014 Lugano Classification for Lymphoma). Secondary outcomes include overall response rate (ORR), 2-year progression-free survival (PFS), 2-year overall survival (OS), and the incidence of treatment-related adverse events (graded per NCI-CTCAE Version 5.0). 40 participants will be enrolled across multiple Chinese medical centers. This Phase 2 trial will provide preliminary evidence to determine whether the golidocitinib combination regimen is a safe and effective first-line option for advanced or non-nasal ENKTL.",[63],"Extranodal NK\u002FT-cell Lymphoma","2026-01-27",{"date":66,"type":40},"2026-02-04",{"date":68,"type":22},"2026-01-25",{"date":70,"type":22},"2032-12-31",{"name":46,"class":47},""]